trending Market Intelligence /marketintelligence/en/news-insights/trending/jzsxayb4b4fkp6xjlgawrg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Alnylam's kidney disease drug granted EU priority designation

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Alnylam's kidney disease drug granted EU priority designation

Cambridge, Mass.-based Alnylam Pharmaceuticals Inc. said its drug lumasiran was granted accelerated assessment under the European Medicines Agency's priority medicines scheme to treat kidney and urinary tract disease.

The EU agency granted lumasiran the designation for treating Primary Hyperoxaluria Type 1, a disease in which crystals build up in the kidneys and urinary tract. The illness results in pain due to kidney stones.

Alnylam said the designation was based on results from the ongoing phase 1/2 study of the drug.

The regulator grants the designation to enhance support for medicines that address an unmet medical need and where early clinical data show the potential to benefit patients.

Alnylam plans to advance the drug to a phase 3 study in the latter part of 2018.

Lumasiran was previously granted breakthrough therapy designation by the U.S. Food and Drug Administration.

Meanwhile, Sanofi previously decided against exercising an option to develop lumasiran under a rare disease collaboration agreed upon in January 2014.